<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390763</url>
  </required_header>
  <id_info>
    <org_study_id>CNIS793B12201</org_study_id>
    <secondary_id>2020-000349-14</secondary_id>
    <nct_id>NCT04390763</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)</brief_title>
  <acronym>daNIS-1</acronym>
  <official_title>A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and&#xD;
      without spartalizumab in combination with gemcitabine/nab-paclitaxel versus&#xD;
      gemcitabine/nab-paclitaxel in untreated mPDAC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">May 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 8, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of DLTs during the Safety Run-in</measure>
    <time_frame>8 months</time_frame>
    <description>Incidence of DLTs to assess the safety and tolerability of NIS793 + spartalizumab in combination with gemcitabine/nab-paclitaxel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of treatment emergent Adverse Events and Serious Adverse Events in Safety Run-in</measure>
    <time_frame>8 months</time_frame>
    <description>Safety and tolerability measured by appearance of (or worsening of any pre-existing condition) undesirable sign(s), symptom(s), or medical condition(s) that occur after patient signed informed consent.&#xD;
A Serious Adverse Event (SAE) is defined as one of the following:&#xD;
Is fatal or life threatening&#xD;
Results in persistent or significant disability/incapacity&#xD;
Constitutes a congenital anomaly/birth defect&#xD;
Is medical significant&#xD;
Requires inpatient hospitalization or prolongation of existing hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose interruptions/reductions in Safety Run-in</measure>
    <time_frame>8 months</time_frame>
    <description>Tolerability of NIS793 + spartalizumab in combination with gemcitabine/nab-paclitaxel measured by the number of subjects with at least one dose interruption/reduction of study treatment and reason</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity in Safety Run-in</measure>
    <time_frame>8 months</time_frame>
    <description>Tolerability of NIS793 + spartalizumab in combination with gemcitabine/nab-paclitaxel measured by the dose intensity of study treatment for subjects with non-zero duration of exposure computed as the ratio of dose intensity and planned dose intensity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival in Randomized part</measure>
    <time_frame>18 months</time_frame>
    <description>PFS as per Response Evaluation Criteria in Solid Tumors (RECIST1.1) as per local Investigator's review, to evaluate the PFS of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Adverse Events and Serious Adverse Events in Randomized part</measure>
    <time_frame>18 months</time_frame>
    <description>Safety and tolerability measured by appearance of (or worsening of any pre-existing condition) undesirable sign(s), symptom(s), or medical condition(s) that occur after patient signed informed consent.&#xD;
A Serious Adverse Event (SAE) is defined as one of the following:&#xD;
Is fatal or life threatening&#xD;
Results in persistent or significant disability/incapacity&#xD;
Constitutes a congenital anomaly/birth defect&#xD;
Is medical significant&#xD;
Requires inpatient hospitalization or prolongation of existing hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate per RECIST 1.1 in Randomized part</measure>
    <time_frame>18 months</time_frame>
    <description>ORR per RECIST 1.1 to assess the preliminary anti-tumor activity of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response per RECIST 1.1 in Randomized part</measure>
    <time_frame>18 months</time_frame>
    <description>DOR per RECIST 1.1 to assess the preliminary anti-tumor activity of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression per RECIST 1.1 in Randomized part</measure>
    <time_frame>18 months</time_frame>
    <description>TTP per RECIST 1.1 to assess the preliminary anti-tumor activity of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival per RECIST 1.1 in Randomized part</measure>
    <time_frame>18 months</time_frame>
    <description>OS per RECIST 1.1 to assess the preliminary anti-tumor activity of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 and PD-L1 expression in Randomized part</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in CD8 and PD-L1 IHC related markers to assess the CD8 and PD-L1 status of the participants at screening and on treatment versus gemcitabine/nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA) (anti-NIS793 and anti-spartalizumab) expression in Randomized part</measure>
    <time_frame>18 months</time_frame>
    <description>Antidrug antibodies (ADA) prevalence at baseline and ADA incidence on-treatment (anti-NIS793 and anti-spartalizumab) to characterize the incidence of immunogenicity of NIS793 and spartalizumab in combination with gemcitabine/nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter Cmax in Randomized part</measure>
    <time_frame>12 months</time_frame>
    <description>To characterize the pharmacokinetics (PK) of NIS793, spartalizumab, gemcitabine/nab-paclitaxel in combination treatment or alone (gemcitabine/nab-paclitaxel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter AUClast in Randomized part</measure>
    <time_frame>12 months</time_frame>
    <description>To characterize the pharmacokinetics (PK) of NIS793, spartalizumab, gemcitabine/nab-paclitaxel in combination treatment or alone (gemcitabine/nab-paclitaxel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter Ctrough</measure>
    <time_frame>12 months</time_frame>
    <description>To characterize the pharmacokinetics (PK) of NIS793, spartalizumab, gemcitabine/nab-paclitaxel in combination treatment or alone (gemcitabine/nab-paclitaxel)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">161</enrollment>
  <condition>Metastatic Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Safety Run-in</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of NIS793 + gemcitabine + nab-paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gemcitabine + nab-paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NIS793</intervention_name>
    <description>anti-TGFb antibody</description>
    <arm_group_label>Randomized Arm 1</arm_group_label>
    <arm_group_label>Randomized Arm 2</arm_group_label>
    <arm_group_label>Safety Run-in</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Spartalizumab</intervention_name>
    <description>anti-PD-1 antibody</description>
    <arm_group_label>Randomized Arm 1</arm_group_label>
    <arm_group_label>Safety Run-in</arm_group_label>
    <other_name>PDR001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>SOC chemotherapy</description>
    <arm_group_label>Randomized Arm 1</arm_group_label>
    <arm_group_label>Randomized Arm 2</arm_group_label>
    <arm_group_label>Randomized Arm 3</arm_group_label>
    <arm_group_label>Safety Run-in</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>SOC chemotherapy</description>
    <arm_group_label>Randomized Arm 1</arm_group_label>
    <arm_group_label>Randomized Arm 2</arm_group_label>
    <arm_group_label>Randomized Arm 3</arm_group_label>
    <arm_group_label>Safety Run-in</arm_group_label>
    <other_name>abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent must be obtained prior to participation in the study.&#xD;
&#xD;
          2. Male or female ≥ 18 years of age at the time of informed consent.&#xD;
&#xD;
          3. Participants with histologically or cytologically confirmed treatment-naïve metastatic&#xD;
             adenocarcinoma of the pancreas with measurable disease as per RECIST 1.1.&#xD;
&#xD;
          4. Participants must have a site of disease amenable to biopsy, and be candidate for&#xD;
             tumor biopsy according to the treating institution's guidelines. Participants must be&#xD;
             willing to undergo a tumor biopsy at screening and during therapy on the study. In the&#xD;
             event a new biopsy cannot be safely performed at study entry, an archival sample&#xD;
             (collected &lt;6 months prior) may be substituted following documented discussion with&#xD;
             Novartis.&#xD;
&#xD;
          5. ECOG performance status ≤ 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous radiotherapy, surgery (with exception of placement of biliary stent, which is&#xD;
             allowed), chemotherapy or any other investigational therapy for the treatment of&#xD;
             metastatic pancreatic cancer. Participants having received previous chemotherapy in&#xD;
             the adjuvant setting.&#xD;
&#xD;
          2. Participants amenable to potentially curative resection.&#xD;
&#xD;
          3. Participants with a diagnosis of pancreatic neuroendocrine tumors (NETs), acinar, or&#xD;
             islet cell tumors.&#xD;
&#xD;
          4. Having out of range laboratory values as pre-defined in the protocol.&#xD;
&#xD;
          5. Participants with MSI-H pancreatic adenocarcinoma.&#xD;
&#xD;
          6. Presence of symptomatic CNS metastases, or CNS metastases that require local CNS&#xD;
             directed therapy (such as radiotherapy or surgery), or increasing doses of&#xD;
             corticosteroids 2 weeks prior to study entry.&#xD;
&#xD;
          7. History of severe hypersensitivity reactions to any ingredient of study drug(s) and&#xD;
             other mAbs and/or their excipients.&#xD;
&#xD;
          8. The participant exhibits any of the events outlined in the contra-indications or&#xD;
             special warnings and precautions sections of gemcitabine and nab-paclitaxel as per&#xD;
             locally approved labels.&#xD;
&#xD;
          9. Impaired cardiac function or clinically significant cardiac disease.&#xD;
&#xD;
         10. Known history of testing positive HIV infection.&#xD;
&#xD;
         11. Active HBV or HCV infection. Participants whose disease is controlled under antiviral&#xD;
             therapy should not be excluded.&#xD;
&#xD;
         12. History of or current interstitial lung disease or pneumonitis grade ≥ 2&#xD;
&#xD;
         13. High risk of clinically significant gastrointestinal tract bleeding or any other&#xD;
             condition associated with or history of significant bleeding.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Escobar</last_name>
      <phone>404-778-1900</phone>
      <email>alicia.m.escobar@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Maria Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Med</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charmaine Stephens</last_name>
      <phone>410-955-5222</phone>
      <email>csteph13@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Laheru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abbi Smith</last_name>
      <email>ASMITH137@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Colin Weekes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Cente</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Peters</last_name>
      <phone>617-667-7000</phone>
      <email>mbpeters@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Bruno Bockorny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute HIllman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jocelyn Joseph</last_name>
      <phone>412-623-7901</phone>
      <email>josephj11@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Anuradha Krishnamurthy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HUS</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 4</city>
        <zip>31054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NIS793, spartalizumab, gemcitabine, nab-paclitaxel, mPDAC, TGFβ, PD-1, Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

